Invention Grant
US08460914B2 Decreasing potential iatrogenic risks associated with vaccines and vaccine antigens
有权
降低与疫苗和疫苗抗原相关的潜在医源性风险
- Patent Title: Decreasing potential iatrogenic risks associated with vaccines and vaccine antigens
- Patent Title (中): 降低与疫苗和疫苗抗原相关的潜在医源性风险
-
Application No.: US13738929Application Date: 2013-01-10
-
Publication No.: US08460914B2Publication Date: 2013-06-11
- Inventor: Jens-Peter Gregersen
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Priority: EP04255471 20040909
- Main IPC: C12N7/02
- IPC: C12N7/02 ; A61K39/00

Abstract:
Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections.
Public/Granted literature
- US20130122487A1 DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES Public/Granted day:2013-05-16
Information query